The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II randomized trial of radiotherapy with pembrolizumab vs. cisplatin for unfavorable-risk p16+ head and neck squamous cell carcinoma (KEYCHAIN).
 
Loren Mell
Consulting or Advisory Role - Johnson & Johnson
Research Funding - Merck
 
Assuntina Sacco
Employment - Moores Cancer Center
Consulting or Advisory Role - Johnson and Johnson; Tempus
Research Funding - ALX Oncology (Inst); AstraZeneca (Inst); Bicara Therapeutics (Inst); Genentech/Roche (Inst); Infinity Pharmaceuticals (Inst); ITeos Therapeutics (Inst); Janssen Oncology (Inst); Jazz Pharmaceuticals (Inst); Merck (Inst); Merus (Inst); Regeneron (Inst); Seagen (Inst); Toragen (Inst)
 
Jingjing Zou
No Relationships to Disclose
 
Trisha Wise-Draper
Stock and Other Ownership Interests - High Enroll
Consulting or Advisory Role - Adaptimmune; Adlai Nortye; Caris Life Sciences; EMD Serono; Genmab; Johnson & Johnson/Janssen; Merck; Need; Replimune
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb; Caris Life Sciences; GlaxoSmithKline; GlaxoSmithKline; Janssen Oncology; Merck
Travel, Accommodations, Expenses - Caris Life Sciences; Precisca
 
Andrew Sharabi
No Relationships to Disclose
 
Ricklie Julian
Consulting or Advisory Role - AstraZeneca; Merck
Travel, Accommodations, Expenses - BioAtla
 
Jing Zhang
No Relationships to Disclose
 
Jared Robbins
No Relationships to Disclose
 
Jimmy Caudell
No Relationships to Disclose
 
Natalie Lockney
No Relationships to Disclose
 
Kathryn Gold
No Relationships to Disclose
 
Julie Bauman
Consulting or Advisory Role - AVEO (Inst); BlueDot (Inst); Johnson & Johnson/Janssen
Research Funding - AstraZeneca (Inst); AVEO (Inst); BioNTech SE (Inst); Celldex (Inst); CUE Biopharma (Inst); Moderna Therapeutics (Inst)
 
Emily Pittman
No Relationships to Disclose
 
Karen Yun
No Relationships to Disclose
 
Parag Sanghvi
No Relationships to Disclose
 
Wade Thorstad
Employment - Elekta (I)
Travel, Accommodations, Expenses - Elekta (I)
 
Joseph Califano
No Relationships to Disclose
 
Ezra Cohen
Employment - Tempus
(OPTIONAL) Uncompensated Relationships - Flamingo Therapeutics - Board of Directors
 
Karen Messer
No Relationships to Disclose
 
Douglas Adkins
Consulting or Advisory Role - Adcendo; Adlai Nortye; AstraZeneca; Boehringer Ingelheim; CUE Biopharma; Genmab/Seattle Genetics; GlaxoSmithKline; Immunitas; InhibRx; Johnson & Johnson/Janssen; Kura Oncology; Merck; Merus; Purple Biotech; Pyxis; Regeneron; Tubulis GmbH
Research Funding - Adlai Nortye (Inst); Alentis Therapeutics (Inst); AstraZeneca (Inst); AVEO (Inst); BeiGene (Inst); BioAtla (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calliditas Therapeutics (Inst); Celgene (Inst); Cofactor Genomics (Inst); Coherus Biosciences (Inst); CUE Biopharma (Inst); Daiichi Sankyo Europe GmbH (Inst); Debiopharm Group (Inst); Epizyme (Inst); Erasca, Inc (Inst); Exelixis (Inst); Genmab (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hookipa Biotech (Inst); Immutep (Inst); InhibRx (Inst); ISA Pharmaceuticals (Inst); Johnson & Johnson/Janssen (Inst); Kura Oncology (Inst); Lilly (Inst); Merck (Inst); Merus (Inst); NATCO Pharma (Inst); Novartis (Inst); Pfizer (Inst); Rgenta (Inst); Roche (Inst); Seagen (Inst); Takeda (Inst); Tempus (Inst); Tizona Therapeutics, Inc. (Inst); Vaccinex (Inst); Xilio Therapeutics (Inst)